Avivagen Inc. Declares Bankruptcy Amid Market Challenges
Avivagen Announces New Orders for 1.1 Tonnes of OxC-beta Livestock Product
Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2023
Avivagen Inc. (TSXV:VIV) has announced its unaudited financial results for the Second quarter of 2023.
An Existing Avivagen Customer Increases Order Size
Avivagen Inc. Provides Update on Securities for Service Agreements With CEO and CSO
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal
Avivagen GAAP EPS of -$0.01, Revenue of $0.07M
Avivagen Reports FY Results
Avivagen Inc. Announces Securities for Service Agreements With CEO and CSO
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal
Avivagen Inc. Announces Closing of Second Tranche of a Private Placement of Shares
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal
Avivagen Inc. (OTCMKTS:VIVXF) Sees Significant Drop in Short Interest
Avivagen Inc. (OTCMKTS:VIVXF – Get Rating) was the recipient of a significant drop in short interest in October. As of October 15th, there was short interest totalling 2,800 shares, a drop of 64.6%
Avivagen Inc. Announces Closing of First Tranche of a Non-Brokered Private Placement of Shares for Proceeds of up to $1.0 Million
**Not for Distribution to United States News Wire Services or for Dissemination in the United States.** OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) ("Avivagen" or the "Company"), a life
Avivagen Inc. Announces Proposed Non-Brokered Private Placement of Common Shares for Proceeds of up to $1.0 Million
**NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.** OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) ("Avivagen" or the "Company"), a life
Avivagen Reports Q3 Results
Avivagen press release (OTCQB:VIVXF): Q3 Comprehensive loss of C$1.90M Revenue of C$48.61K (-94.5% Y/Y).
FY2022 EPS Estimates for Avivagen Inc. Decreased by Zacks Small Cap (OTCMKTS:VIVXF)
Avivagen Inc. (OTCMKTS:VIVXF – Get Rating) – Investment analysts at Zacks Small Cap reduced their FY2022 EPS estimates for shares of Avivagen in a note issued to investors on Wednesday, August 31s
Brokers Offer Predictions for Avivagen Inc.'s FY2024 Earnings (OTCMKTS:VIVXF)
Avivagen Inc. (OTCMKTS:VIVXF – Get Rating) – Investment analysts at Zacks Small Cap issued their FY2024 earnings per share (EPS) estimates for Avivagen in a note issued to investors on Wednesday,
Avivagen Inc. Announces Closing of Third Tranche of a Private Placement of Shares and Warrants
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal
Avivagen Inc. Announces Closing of Second Tranche of a Private Placement of Shares and Warrants for Proceeds of Up to $5.0 Million
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.OTTAWA, Ontario, May 31, 2022--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) ("Avivagen" or the "Company"
BRIEF-Avivagen Inc Announces Closing Of Second Tranche Of A Private Placement Of Shares And Warrants For Proceeds Of Up To $5.0 Million
May 31 (Reuters) - Avivagen Inc VIV.V :* AVIVAGEN INC. ANNOUNCES CLOSING OF SECOND TRANCHE OF A PRIVATE PLACEMENT OF SHARES AND WARRANTS FOR PROCEEDS OF UP TO $5.0 MILLIONSource text for Eikon: ID:n
BRIEF-Avivagen Inc - Oxidized Carotenoid-Based Feed Additive Product Has Received Approval For Use In China
May 12 (Reuters) - Avivagen Inc VIV.V :* AVIVAGEN INC - OXIDIZED CAROTENOID-BASED FEED ADDITIVE PRODUCT HAS RECEIVED APPROVAL FOR USE IN CHINASource text for Eikon: ID:nBw6Lm0Ga Further company cov
VIVXF: OxC-beta Approved in Vietnam…
By David Bautz, PhDOTC:VIVXFREAD THE FULL VIVXF RESEARCH REPORTBusiness UpdateOxC-beta Approved in Vietnam; Looking for Sales Ramp in 2H22Avivagen, Inc. (OTC:VIVXF) is developing products to support
No Data